Progress and prospects for blood-stage malaria vaccines

References

• WHO. World Malaria Report 2014; [cited 23 Oct 2015]. Available from: http://www.who.int/malaria/publications/world_malaria_report_2014/en/
   Google Scholar
• Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–211.
   PubMed Web of Science ®Google Scholar
• White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet. 2014;383:723–735.
   PubMed Web of Science ®Google Scholar
• Kaslow DC, Biernaux S. RTS, S: toward a first landmark on the Malaria Vaccine Technology Roadmap. Vaccine. 2015 pii: S0264-410X(15)01337-7. doi:10.1016/j.vaccine.2015.09.061.
   Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45.
   PubMed Web of Science ®Google Scholar
• White MT, Verity R, Griffin JT, et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015 pii: S1473-3099(15)00239-X. doi:10.1016/S1473-3099(15)00239-X.
   Web of Science ®Google Scholar
• Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28:51–60.
   PubMed Web of Science ®Google Scholar
• Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature. 1961;192:733–737.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. 1991;45:297–308.
   PubMed Web of Science ®Google Scholar
• WHO. Malaria Vaccine Technology Roadmap November 2013; [cited 23 Oct 2015]. Available from: http://www.who.int/immunization/topics/malaria/vaccine_roadmap/en/
   Google Scholar
• Tuikue-Ndam N, Deloron P. Developing vaccines to prevent malaria in pregnant women. Expert Opin Biol Ther. 2015;15:1173–1182.
   PubMed Web of Science ®Google Scholar
• Mueller I, Shakri AR, Chitnis CE. Development of vaccines for Plasmodium vivax malaria. Vaccine. 2015 pii: S0264-410X(15)01336-5. doi:10.1016/j.vaccine.2015.09.060.
   Web of Science ®Google Scholar
• Morrison C. Landmark green light for Mosquirix malaria vaccine. Nat Biotechnol. 2015;33:1015–1016.
   PubMed Web of Science ®Google Scholar
• Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A. 2010;107:6958–6963.
   PubMed Web of Science ®Google Scholar
• Malkin E, Hu J, Li Z, et al. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine. 2008;26:6864–6873.
   PubMed Web of Science ®Google Scholar
• Hu J, Chen Z, Gu J, et al. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One. 2008;3:e1952.
   PubMed Web of Science ®Google Scholar
• Fowkes FJ, Richards JS, Simpson JA, et al. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 2010;7:e1000218.
   PubMed Web of Science ®Google Scholar
• Duncan CJ, Hill AV. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother. 2012;8:706–714.
   PubMed Web of Science ®Google Scholar
• Richards JS, Stanisic DI, Fowkes FJ, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis. 2010;51:e50–60.
   PubMed Web of Science ®Google Scholar
• Rono J, Osier FH, Olsson D, et al. Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum infections and protection against clinical malaria. Clin Infect Dis. 2013;57:1409–1416.
   PubMed Web of Science ®Google Scholar
• Moss DK, Remarque EJ, Faber BW, et al. Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development. Infect Immun. 2012;80:1280–1287.
   PubMed Web of Science ®Google Scholar
• Bergmann-Leitner ES, Duncan EH, Mullen GE, et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg. 2006;75:437–442.
   PubMed Web of Science ®Google Scholar
• Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun. 2005;73:3677–3685.
   PubMed Web of Science ®Google Scholar
• Polhemus ME, Magill AJ, Cummings JF, et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 2007;25:4203–4212.
   PubMed Web of Science ®Google Scholar
• Roestenberg M, Remarque E, De Jonge E, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One. 2008;3:e3960.
   PubMed Web of Science ®Google Scholar
• Ellis RD, Martin LB, Shaffer D, et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One. 2010;5:e8787.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Patel SM, Atmar RL, et al. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010;17:1552–1559.
   PubMed Web of Science ®Google Scholar
• Dicko A, Diemert DJ, Sagara I, et al. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One. 2007;2:e1045.
   PubMed Web of Science ®Google Scholar
• Thera MA, Doumbo OK, Coulibaly D, et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One. 2008;3:e1465.
   PubMed Web of Science ®Google Scholar
• Miura K, Zhou H, Diouf A, et al. Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized. Vaccine. 2011;29:2255–2261.
   PubMed Web of Science ®Google Scholar
• Miura K, Perera S, Brockley S, et al. Non-Apical Membrane Antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay. PLoS One. 2011;6:e20947.
   PubMed Web of Science ®Google Scholar
• Miura K, Zhou H, Moretz SE, et al. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol. 2008;181:8776–8783.
   PubMed Web of Science ®Google Scholar
• Duncan CJ, Sheehy SH, Ewer KJ, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One. 2011;6:e22271.
   PubMed Web of Science ®Google Scholar
• Dutta S, Sullivan JS, Grady KK, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One. 2009;4:e8138.
   PubMed Web of Science ®Google Scholar
• Singh S, Miura K, Zhou H, et al. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun. 2006;74:4573–4580.
   PubMed Web of Science ®Google Scholar
• Boyle MJ, Reiling L, Feng G, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity. 2015;42:580–590.
   PubMed Web of Science ®Google Scholar
• Boyle MJ, Wilson DW, Richards JS, et al. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U S A. 2010;107:14378–14383.
   PubMed Web of Science ®Google Scholar
• Bouharoun-Tayoun H, Oeuvray C, Lunel F, et al. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Biol. 1995;182:409–418.
   Web of Science ®Google Scholar
• Bouharoun-Tayoun H, Attanath P, Sabchareon A, et al. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990;172:1633–1641.
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Marjason J, Elliott S, et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide ISA 720. PLoS One. 2011;6:e24413.
   PubMed Web of Science ®Google Scholar
• Druilhe P, Spertini F, Soesoe D, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med. 2005;2:e344.
   PubMed Web of Science ®Google Scholar
• Hermsen CC, Verhage DF, Telgt DS, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine. 2007;25:2930–2940.
   PubMed Web of Science ®Google Scholar
• Yagi M, Bang G, Tougan T, et al. Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences. PLoS One. 2014;9:e98460.
   PubMed Web of Science ®Google Scholar
• Chimma P, Roussilhon C, Sratongno P, et al. A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria. PLoS Pathog. 2009;5:e1000631.
   PubMed Web of Science ®Google Scholar
• Shi YP, Udhayakumar V, Oloo AJ, et al. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am J Trop Med Hyg. 1999;60:135–141.
   PubMed Web of Science ®Google Scholar
• Tiendrebeogo RW, Adu B, Singh SK, et al. High-throughput tri-colour flow cytometry technique to assess Plasmodium falciparum parasitaemia in bioassays. Malar J. 2014;13:412.
   PubMed Web of Science ®Google Scholar
• Hill DL, Eriksson EM, Li Wai Suen CS, et al. Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One. 2013;8:e74627.
   PubMed Web of Science ®Google Scholar
• Osier FH, Feng G, Boyle MJ, et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med. 2014;12:108.
   PubMed Web of Science ®Google Scholar
• Ghumra A, Khunrae P, Ataide R, et al. Immunisation with recombinant PfEMP1 domains elicits functional rosette-inhibiting and phagocytosis-inducing antibodies to Plasmodium falciparum. PLoS One. 2011;6:e16414.
   PubMed Web of Science ®Google Scholar
• Chan JA, Howell KB, Reiling L, et al. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. J Clin Invest. 2012;122:3227–3238.
   PubMed Web of Science ®Google Scholar
• Zhou J, Feng G, Beeson J, et al. CD14(hi)CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so. BMC Med. 2015;13:154.
   PubMed Web of Science ®Google Scholar
• Fleit HB, Kobasiuk CD. The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII. J Leukoc Biol. 1991;49:556–565.
   PubMed Web of Science ®Google Scholar
• Gilson PR, Crabb BS. Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites. Int J Parasitol. 2009;39:91–96.
   PubMed Web of Science ®Google Scholar
• Boyle MJ, Wilson DW, Richards JS, et al. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci USA. 2010;107:14378–14383.
   PubMed Web of Science ®Google Scholar
• Chan JA, Fowkes FJ, Beeson JG. Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cell Mol Life Sci. 2014;71:3633–3657.
   PubMed Web of Science ®Google Scholar
• Bengtsson A, Joergensen L, Rask TS, et al. A novel domain cassette identifies Plasmodium falciparum PfEMP1 proteins binding ICAM-1 and is a target of cross-reactive, adhesion-inhibitory antibodies. J Immunol. 2013;190:240–249.
   PubMed Web of Science ®Google Scholar
• Angeletti D, Albrecht L, Wahlgren M, et al. Analysis of antibody induction upon immunization with distinct NTS-DBL1alpha-domains of PfEMP1 from rosetting Plasmodium falciparum parasites. Malar J. 2013;12:32.
   PubMed Web of Science ®Google Scholar
• Guillotte M, Juillerat A, Igonet S, et al. Immunogenicity of the Plasmodium falciparum PfEMP1-VarO adhesin: induction of surface-reactive and rosette-disrupting antibodies to VarO infected erythrocytes. PLoS One. 2015;10:e0134292.
   Web of Science ®Google Scholar
• Hviid L, Jensen AT. PfEMP1 - a parasite protein family of key importance in Plasmodium falciparum malaria immunity and pathogenesis. Adv Parasitol. 2015;88:51–84.
   PubMed Web of Science ®Google Scholar
• Joos C, Marrama L, Polson HE, et al. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One. 2010;5:e9871.
   PubMed Web of Science ®Google Scholar
• Llewellyn D, Miura K, Fay MP, et al. Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria. Sci Rep. 2015;5:14081.
   PubMed Web of Science ®Google Scholar
• Baruch DI, Gamain B, Miller LH. DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses. Infect Immun. 2003;71:4536–4543.
   PubMed Web of Science ®Google Scholar
• Gullingsrud J, Saveria T, Amos E, et al. Structure-function-immunogenicity studies of PfEMP1 domain DBL2betaPF11_0521, a malaria parasite ligand for ICAM-1. PLoS One. 2013;8:e61323.
   PubMed Web of Science ®Google Scholar
• Jeppesen A, Ditlev SB, Soroka V, et al. Multiple Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) variants per genome can bind IgM via Fcμ. Infect Immun. 2015;83:3972–3981.
   PubMed Web of Science ®Google Scholar
• Lennartz F, Bengtsson A, Olsen RW, et al. Mapping the binding site of a cross-reactive Plasmodium falciparum PfEMP1 monoclonal antibody inhibitory of ICAM-1 binding. J Immunol. 2015;195:3273–3283.
   PubMed Web of Science ®Google Scholar
• Ockenhouse CF, Angov E, Kester KE, et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine. 2006;24:3009–3017.
   PubMed Web of Science ®Google Scholar
• Nebie I, Diarra A, Ouedraogo A, et al. Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Parasite Immunol. 2009;31:474–480.
   PubMed Web of Science ®Google Scholar
• Spring MD, Cummings JF, Ockenhouse CF, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One. 2009;4:e5254.
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012;7:e31208.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Choudhary P, Elias SC, et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1 - report on a phase Ia clinical trial. Mol Ther. 2014;22:2142–2154.
   PubMed Web of Science ®Google Scholar
• Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002;360:610–617.
   PubMed Web of Science ®Google Scholar
• Edstein MD, Kotecka BM, Anderson KL, et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother. 2005;49:4421–4422.
   PubMed Web of Science ®Google Scholar
• Collins WE, Walduck A, Sullivan JS, et al. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys. Am J Trop Med Hyg. 2000;62:466–479.
   PubMed Web of Science ®Google Scholar
• Stowers AW, Kennedy MC, Keegan BP, et al. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun. 2002;70:6961–6967.
   PubMed Web of Science ®Google Scholar
• Carvalho LJ, Oliveira SG, Theisen M, et al. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol. 2004;59:363–372.
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Alba MP, Curtidor H, et al. Using the PfEMP1 head structure binding motif to deal a blow at severe malaria. PLoS One. 2014;9:e88420.
   PubMed Web of Science ®Google Scholar
• Douglas AD, Williams AR, Knuepfer E, et al. Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J Immunol. 2014;192:245–258.
   PubMed Web of Science ®Google Scholar
• Stowers AW, Miller LH. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol. 2001;17:415–419.
   PubMed Web of Science ®Google Scholar
• Herrera S, Perlaza BL, Bonelo A, et al. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int J Parasitol. 2002;32:1625–1635.
   PubMed Web of Science ®Google Scholar
• Sturchler D, Berger R, Rudin C, et al. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am J Trop Med Hyg. 1995;53:423–431.
   PubMed Web of Science ®Google Scholar
• Ockenhouse CF, Sun PF, Lanar DE, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis. 1998;177:1664–1673.
   PubMed Web of Science ®Google Scholar
• Sedegah M, Tamminga C, McGrath S, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One. 2011;6:e24586.
   PubMed Web of Science ®Google Scholar
• Thompson FM, Porter DW, Okitsu SL, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One. 2008;3:e1493.
   PubMed Web of Science ®Google Scholar
• Tamminga C, Sedegah M, Maiolatesi S, et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccin Immunother. 2013;9:2165–2177.
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012;20:2355–2368.
   PubMed Web of Science ®Google Scholar
• Lawrence G, Cheng QQ, Reed C, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. 2000;18:1925–1931.
   PubMed Web of Science ®Google Scholar
• Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2010;11:57–64.
   Web of Science ®Google Scholar
• Engwerda CR, Minigo G, Amante FH, et al. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 2012;28:515–521.
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Douglas AD, Draper SJ. Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother. 2013;9:1831–1840.
   PubMed Web of Science ®Google Scholar
• Teirlinck AC, Roestenberg M, Van De Vegte-Bolmer M, et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis. 2012;207:656–660.
   PubMed Web of Science ®Google Scholar
• Stanisic DI, Liu XQ, De SL, et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J. 2015;14:143.
   PubMed Web of Science ®Google Scholar
• Siu E, Ploss A. Modeling malaria in humanized mice: opportunities and challenges. Ann N Y Acad Sci. 2015;1342:29–36.
   PubMed Web of Science ®Google Scholar
• Chen Q, Amaladoss A, Ye W, et al. Human natural killer cells control Plasmodium falciparum infection by eliminating infected red blood cells. Proc Natl Acad Sci U S A. 2014;111:1479–1484.
   PubMed Web of Science ®Google Scholar
• Wijayalath W, Majji S, Villasante EF, et al. Humanized HLA-DR4.RagKO.IL2RgammacKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria. Malar J. 2014;13:386.
   PubMed Web of Science ®Google Scholar
• Huang J, Li X, Coelho-Dos-Reis JG, et al. Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria. J Immunol Methods. 2015 pii: S0022-1759(15)30047-8. doi:10.1016/j.jim.2015.09.005.
   Web of Science ®Google Scholar
• Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002;185:820–827.
   PubMed Web of Science ®Google Scholar
• Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011;365:1004–1013.
   PubMed Web of Science ®Google Scholar
• Sirima SB, Cousens S, Druilhe P. Protection against malaria by MSP3 candidate vaccine. N Engl J Med. 2011;365:1062–1064.
   PubMed Web of Science ®Google Scholar
• Palacpac NM, Ntege E, Yeka A, et al. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. PLoS One. 2013;8:e64073.
   PubMed Web of Science ®Google Scholar
• WHO. Malaria rainbow tables; [cited 2015 Oct 23]. Available from: http://www.who.int/immunization/research/development/Rainbow_tables/en/
   Google Scholar
• ClinicalTrial.gov; [cited 2015 Oct 23]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Laurens MB, Thera MA, Coulibaly D, et al. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in Malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One. 2013;8:e79323.
   PubMed Web of Science ®Google Scholar
• Sagara I, Dicko A, Ellis RD, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009;27:3090–3098.
   PubMed Web of Science ®Google Scholar
• Ouattara A, Mu J, Takala-Harrison S, et al. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J. 2010;9:175.
   PubMed Web of Science ®Google Scholar
• Mullen GE, Ellis RD, Miura K, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One. 2008;3:e2940.
   PubMed Web of Science ®Google Scholar
• Drew DR, Hodder AN, Wilson DW, et al. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS One. 2012;7:e51023.
   PubMed Web of Science ®Google Scholar
• Dutta S, Dlugosz LS, Drew DR, et al. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog. 2013;9:e1003840.
   PubMed Web of Science ®Google Scholar
• Miura K, Herrera R, Diouf A, et al. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect Immun. 2013;81:1491–1501.
   PubMed Web of Science ®Google Scholar
• Kusi KA, Faber BW, Van Der Eijk M, et al. Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits. Malar J. 2011;10:40.
   PubMed Web of Science ®Google Scholar
• Kusi KA, Remarque EJ, Riasat V, et al. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques. Malar J. 2011;10:182.
   PubMed Web of Science ®Google Scholar
• Harris KS, Adda CG, Khore M, et al. Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1. Infect Immun. 2014;82:4707–4717.
   PubMed Web of Science ®Google Scholar
• Richard D, Macraild CA, Riglar DT, et al. Interaction between Plasmodium falciparum apical membrane antigen 1 and the Rhoptry neck protein complex defines a key step in the erythrocyte invasion process of malaria parasites. J Biol Chem. 2010;285:14815–14822.
   PubMed Web of Science ®Google Scholar
• Srinivasan P, Ekanem E, Diouf A, et al. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci U S A. 2014;111:10311–10316.
   PubMed Web of Science ®Google Scholar
• Tsai CW, Duggan PF, Jin AJ, et al. Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Mol Biochem Parasitol. 2009;164:45–56.
   PubMed Web of Science ®Google Scholar
• Audran R, Cachat M, Lurati F, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun. 2005;73:8017–8026.
   PubMed Web of Science ®Google Scholar
• Jepsen MP, Jogdand PS, Singh SK, et al. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria-endemic and non-endemic areas. J Infect Dis. 2013;208:479–488.
   PubMed Web of Science ®Google Scholar
• Esen M, Kremsner PG, Schleucher R, et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine. 2009;27:6862–6868.
   PubMed Web of Science ®Google Scholar
• Mordmuller B, Szywon K, Greutelaers B, et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine. 2010;28:6698–6703.
   PubMed Web of Science ®Google Scholar
• Belard S, Issifou S, Hounkpatin AB, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One. 2011;6:e22525.
   PubMed Web of Science ®Google Scholar
• Horii T, Shirai H, Jie L, et al. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitol Int. 2010;59:380–386.
   PubMed Web of Science ®Google Scholar
• Darko CA, Angov E, Collins WE, et al. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun. 2005;73:287–297.
   PubMed Web of Science ®Google Scholar
• Lyon JA, Angov E, Fay MP, et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One. 2008;3:e2830.
   PubMed Web of Science ®Google Scholar
• Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One. 2009;4:e4708.
   PubMed Web of Science ®Google Scholar
• Healer J, Thompson JK, Riglar DT, et al. Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum. PLoS One. 2013;8:e72504.
   PubMed Web of Science ®Google Scholar
• Bei AK, Membi CD, Rayner JC, et al. Variant merozoite protein expression is associated with erythrocyte invasion phenotypes in Plasmodium falciparum isolates from Tanzania. Mol Biochem Parasitol. 2007;153:66–71.
   PubMed Web of Science ®Google Scholar
• Villard V, Agak GW, Frank G, et al. Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif. PLoS One. 2007;2:e645.
   PubMed Web of Science ®Google Scholar
• Kulangara C, Luedin S, Dietz O, et al. Cell biological characterization of the malaria vaccine candidate trophozoite exported protein 1. PLoS One. 2012;7:e46112.
   PubMed Web of Science ®Google Scholar
• Olugbile S, Kulangara C, Bang G, et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage associated P. falciparum protein PFF0165c. Infect Immun. 2009;77:5701–5709.
   PubMed Web of Science ®Google Scholar
• Douglas AD, Williams AR, Illingworth JJ, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun. 2011;2:601.
   PubMed Web of Science ®Google Scholar
• Tran TM, Ongoiba A, Coursen J, et al. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis. 2014;209:789–798.
   PubMed Web of Science ®Google Scholar
• Patel SD, Ahouidi AD, Bei AK, et al. Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J Infect Dis. 2013;208:1679–1687.
   PubMed Web of Science ®Google Scholar
• Bustamante LY, Bartholdson SJ, Crosnier C, et al. A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine. 2013;31:373–379.
   PubMed Web of Science ®Google Scholar
• Douglas AD, Baldeviano GC, Lucas CM, et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in Aotus monkeys. Cell Host Microbe. 2015;17:130–139.
   PubMed Web of Science ®Google Scholar
• Chen L, Lopaticki S, Riglar DT, et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog. 2011;7:e1002199.
   PubMed Web of Science ®Google Scholar
• Reddy KS, Amlabu E, Pandey AK, et al. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc Natl Acad Sci U S A. 2015;112:1179–1184.
   PubMed Web of Science ®Google Scholar
• Williams AR, Douglas AD, Miura K, et al. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog. 2012;8:e1002991.
   PubMed Web of Science ®Google Scholar
• Reddy KS, Pandey AK, Singh H, et al. Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Infect Immun. 2014;82:152–164.
   PubMed Web of Science ®Google Scholar
• Richards JS, Arumugam TU, Reiling L, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol. 2013;191:795–809.
   PubMed Web of Science ®Google Scholar
• Osier FH, Mackinnon MJ, Crosnier C, et al. New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med. 2014;6:247ra102.
   PubMed Web of Science ®Google Scholar
• Raj DK, Nixon CP, Nixon CE, et al. Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science. 2014;344:871–877.
   PubMed Web of Science ®Google Scholar
• Ahlborg N, Iqbal J, Bjork L, et al. Plasmodium falciparum: differential parasite growth inhibition mediated by antibodies to the antigens Pf332 and Pf155/RESA. Exp Parasitol. 1996;82:155–163.
   PubMed Web of Science ®Google Scholar
• Balogun HA, Awah NW, Farouk SE, et al. Pf332-C231-reactive antibodies affect growth and development of intra-erythrocytic Plasmodium falciparum parasites. Vaccine. 2011;30:21–28.
   PubMed Web of Science ®Google Scholar
• De Silva HD, Saleh S, Kovacevic S, et al. The antibody response to Plasmodium falciparum merozoite surface protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes. Malar J. 2011;10:266.
   PubMed Web of Science ®Google Scholar
• Zhao X, Chang Z, Tu Z, et al. PfRON3 is an erythrocyte-binding protein and a potential blood-stage vaccine candidate antigen. Malar J. 2014;13:490.
   PubMed Web of Science ®Google Scholar
• Arumugam TU, Takeo S, Yamasaki T, et al. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Infect Immun. 2011;79:4523–4532.
   PubMed Web of Science ®Google Scholar
• Li X, Marinkovic M, Russo C, et al. Identification of a specific region of Plasmodium falciparum EBL-1 that binds to host receptor glycophorin B and inhibits merozoite invasion in human red blood cells. Mol Biochem Parasitol. 2012;183:23–31.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Takeo S, Maier AG, et al. Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes. Vaccine. 2012;30:1972–1980.
   PubMed Web of Science ®Google Scholar
• Chiu CY, Hodder AN, Lin CS, et al. Antibodies to the Plasmodium falciparum proteins MSPDBL1 and MSPDBL2 opsonise merozoites, inhibit parasite growth and predict protection from clinical malaria. J Infect Dis. 2015;212:406–415.
   PubMed Web of Science ®Google Scholar
• Ito D, Hasegawa T, Miura K, et al. RALP1 is a rhoptry-neck erythrocyte-binding protein of Plasmodium falciparum merozoite and a potential blood-stage vaccine candidate antigen. Infect Immun. 2013;81:4290–4298.
   PubMed Web of Science ®Google Scholar
• Ellis RD, Wu Y, Martin LB, et al. Phase 1 study in malaria naive adults of BSAM2/Alhydrogel(R)+CPG 7909, a blood stage vaccine against P. falciparum malaria. PLoS One. 2012;7:e46094.
   PubMed Web of Science ®Google Scholar
• Chitnis CE, Mukherjee P, Mehta S, et al. Phase I clinical trial of a recombinant blood stage vaccine candidate for Plasmodium falciparum malaria based on MSP1 and EBA175. PLoS One. 2015;10:e0117820.
   PubMed Web of Science ®Google Scholar
• Cech PG, Aebi T, Abdallah MS, et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One. 2011;6:e22273.
   PubMed Web of Science ®Google Scholar
• Theisen M, Roeffen W, Singh SK, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine. 2014;32:2623–2630.
   PubMed Web of Science ®Google Scholar
• Boes A, Spiegel H, Voepel N, et al. Analysis of a multi-component multi-stage malaria vaccine candidate-tackling the cocktail challenge. PLoS One. 2015;10:e0131456.
   PubMed Web of Science ®Google Scholar
• Spiegel H, Boes A, Kastilan R, et al. The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines. Biotechnol J. 2015;10:1651–1659.
   PubMed Web of Science ®Google Scholar
• Good MF, Reiman JM, Rodriguez IB, et al. Cross-species malaria immunity induced by chemically attenuated parasites. J Clin Invest. 2013;123:3353–3362.
   Web of Science ®Google Scholar
• Seder RA, Chang L-J, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359–1365.
   PubMed Web of Science ®Google Scholar
• Bojang K, Milligan P, Pinder M, et al. Five year safety and immunogenicity of GlaxoSmithKline’s candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum Vaccin. 2009;5(4):242–247.
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337–346.
   PubMed Web of Science ®Google Scholar
• Pierce MA, Ellis RD, Martin LB, et al. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine. 2010;28:2236–2242.
   PubMed Web of Science ®Google Scholar
• Dutta S, Lee SY, Batchelor AH, et al. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A. 2007;104:12488–12493.
   PubMed Web of Science ®Google Scholar
• Wright KE, Hjerrild KA, Bartlett J, et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature. 2014;515:427–430.
   PubMed Web of Science ®Google Scholar
• Ord RL, Caldeira JC, Rodriguez M, et al. A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Malar J. 2014;13:326.
   PubMed Web of Science ®Google Scholar
• Dunachie S, Berthoud T, Hill AV, et al. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model. Vaccine. 2015;33:5321–5331.
   PubMed Web of Science ®Google Scholar